Compare MLCI & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | AIDX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.1M | 58.8M |
| IPO Year | N/A | N/A |
| Metric | MLCI | AIDX |
|---|---|---|
| Price | $5.08 | $3.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.1K | ★ 379.4K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $2.81 |
| 52 Week High | $8.68 | $14.09 |
| Indicator | MLCI | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 4.89 |
| Support Level | N/A | N/A |
| Resistance Level | $8.06 | N/A |
| Average True Range (ATR) | 0.35 | 1.71 |
| MACD | 0.03 | -0.68 |
| Stochastic Oscillator | 34.55 | 4.34 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.